SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation

H.A. Wakelee, M.-J. Ahn, J. Bradley, S. Popat, K. Kelly, A.-M. Baird, O. Ozyilkan, J. Yu, S.Y. Lee, N. Yanagitani, M. Johnson, A. Sánchez-Hernández, A. Szczesna, K. Cuppens, E. Yao, C. Parsons, C. Matheny, Z. Zhang, M.N. White, J.J. Hsu, N.S. Patil, R. Dziadziuszko

Open source

DOI: 10.1016/j.annonc.2026.07.414
Published: 2026-08
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.07.414,
  title = {SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation},
  author = {H.A. Wakelee and M.-J. Ahn and J. Bradley and S. Popat and K. Kelly and A.-M. Baird and O. Ozyilkan and J. Yu and S.Y. Lee and N. Yanagitani and M. Johnson and A. Sánchez-Hernández and A. Szczesna and K. Cuppens and E. Yao and C. Parsons and C. Matheny and Z. Zhang and M.N. White and J.J. Hsu and N.S. Patil and R. Dziadziuszko},
  year = {2026},
  journal = {Annals of Oncology},
  doi = {10.1016/j.annonc.2026.07.414},
  url = {https://doi.org/10.1016/j.annonc.2026.07.414}
}

RIS

TY  - JOUR
TI  - SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation
AU  - H.A. Wakelee
AU  - M.-J. Ahn
AU  - J. Bradley
AU  - S. Popat
AU  - K. Kelly
AU  - A.-M. Baird
AU  - O. Ozyilkan
AU  - J. Yu
AU  - S.Y. Lee
AU  - N. Yanagitani
AU  - M. Johnson
AU  - A. Sánchez-Hernández
AU  - A. Szczesna
AU  - K. Cuppens
AU  - E. Yao
AU  - C. Parsons
AU  - C. Matheny
AU  - Z. Zhang
AU  - M.N. White
AU  - J.J. Hsu
AU  - N.S. Patil
AU  - R. Dziadziuszko
PY  - 2026
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2026.07.414
UR  - https://doi.org/10.1016/j.annonc.2026.07.414
ER  -

APA

Wakelee, H., Ahn, M., Bradley, J., Popat, S., Kelly, K., Baird, A., Ozyilkan, O., Yu, J., Lee, S., Yanagitani, N., Johnson, M., Sánchez-Hernández, A., Szczesna, A., Cuppens, K., Yao, E., Parsons, C., Matheny, C., Zhang, Z., White, M., Hsu, J., Patil, N., & Dziadziuszko, R. (2026). SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.07.414

Source records

crossref · retrieved 2026-09-25T18:22:38.712Z